Ani Pharmaceuticals (ANIP) Free Cash Flow (2010 - 2026)

Ani Pharmaceuticals has disclosed Free Cash Flow across 17 years of filings, most recently posting $53.6 million for Q2 2026.

• In Q2 2026, Free Cash Flow fell 25.33% year-over-year to $53.6 million; the TTM figure through Jun 2026 stood at $173.0 million (up 37.9% YoY), while the FY2025 annual figure was $171.4 million, up 258.7% from the prior year.
• Free Cash Flow came in at $53.6 million for Q2 2026 at Ani Pharmaceuticals, up from $52.3 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $71.8 million in Q2 2025 to a low of -$20.9 million in Q1 2022.
• Average Free Cash Flow over 5 years is $21.9 million, with a median of $18.6 million recorded in 2023.
• Year-over-year, Free Cash Flow sank 1753.11% in 2022 and surged 2534.63% in 2023.
• Over 5 years, Free Cash Flow stood at -$7.5 million in 2022, then soared by 663.29% to $42.5 million in 2023, then tumbled by 68.29% to $13.5 million in 2024, then surged by 116.27% to $29.1 million in 2025, then soared by 84.1% to $53.6 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were $53.6 million in Q2 2026, $52.3 million in Q1 2026, and $29.1 million in Q4 2025.